Skip to content
DataLookout
Menu

MIRRORNCT06074510

PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer

StatusCompleted
PhasePhase 4
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 11 versions: 10 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 14 words Show 5 more changesShow less
    • Trial completed
    • Enrollment target: estimated 274 to confirmed 279
    • Primary and study completion dates changed from estimate of Sep 2026 to Aug 28, 2026
    • Secondary endpoints: details revised at 3 of 8 entries
    • Site details revised at 1 of 14 sites
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Primary and study completion dates: Nov 2026 to Sep 2026
    • Site details revised at 14 of 14 sites
    v10
  3. Minor Primary and study completion dates pushed to Nov 2026
    • Site contacts updated at 14 of 14 sites
    v8
  4. Notable Primary completion date: Dec 2024 to Jul 2026
    • Study sites: 10 to 14
    • Study completion date: Jan 2026 to Aug 2026
    v7
  5. Minor Study sites: 5 to 10v6
Show 4 earlier versionsHide 4 earlier versions
  1. Minor Study sites: 3 to 5v5
  2. Minor Start date changed from estimate of Feb 2024 to Feb 8, 2024v4
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 3
    v3
  4. Notable Start date: Dec 2023 to Feb 2024
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Detection rate
Timeframe: Day 1

Secondary (8)

Change in intended patient clinical management
True detection rate
Correct localization rate
Positive predictive value of PYLARIFY
Sensitivity of PYLARIFY
Show 3 moreShow less
Specificity of PYLARIFY
Negative predictive value of PYLARIFY
Number of participants with Adverse Events

Arms and interventions

PYLARIFY PETExperimental

Drugs: Piflufolastat F 18 Intravenous Solution [PYLARIFY]

Sites

14 sites in 1 country